{
    "root": "5e039567-37bf-4ae6-aeab-82df1f8b8194",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fenofibrate",
    "value": "20250509",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        }
    ],
    "indications": "fenofibrate tablets peroxisome proliferator-activated receptor ( ppar ) alpha agonist indicated adjunct diet : • reduce elevated ldl-c , total-c , tg apo b , increase hdl-c adult patients primary hypercholesterolemia mixed dyslipidemia ( 1.1 ) . • treatment adult patients severe hypertriglyceridemia ( 1.2 ) . limitations : fenofibrate shown reduce coronary heart disease morbidity mortality patients type 2 diabetes mellitus ( 5.1 ) .",
    "contraindications": "• primary hypercholesterolemia mixed dyslipidemia : initial dose 145 mg daily ( 2.2 ) . • severe hypertriglyceridemia : initial dose 48 145 mg daily . maximum dose 145 mg ( 2.3 ) . • renally impaired patients : initial dose 48 mg daily ( 2.4 ) . • geriatric patients : select dose basis renal function ( 2.5 ) . • may taken without regard meals ( 2.1 ) .",
    "warningsAndPrecautions": "fenofibrate tablets , usp available containing 145 mg fenofibrate , usp . 145 mg tablets white , film-coated , oval , unscored tablets debossed one side tablet fe4 side . available follows : ndc 68788-7932-3 bottles 30 tablets ndc 68788-7932-6 bottles 60 tablets ndc 68788-7932-9 bottles 90 tablets ndc 68788-7932-1 bottles 100 tablets dispense tight , light-resistant container defined usp using child-resistant closure .",
    "adverseReactions": "fenofibrate tablets contraindicated : •patients severe renal impairment , including receiving dialysis [ pharmacology ( 12.3 ) ] . •patients active liver disease , including primary biliary cirrhosis unexplained persistent liver function abnormalities [ ( 5.2 ) ] . •patients preexisting gallbladder disease [ ( 5.5 ) ] . •nursing mothers [ ( 8.2 ) ] . •patients known hypersensitivity fenofibrate fenofibric acid [ ( 5.9 ) ] .",
    "indications_original": "Fenofibrate tablets are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: • To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). • For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications_original": "• Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 145 mg once daily ( 2.2 ). • Severe hypertriglyceridemia: Initial dose of 48 to 145 mg once daily. Maximum dose is 145 mg ( 2.3 ). • Renally impaired patients: Initial dose of 48 mg once daily ( 2.4 ). • Geriatric patients: Select the dose on the basis of renal function ( 2.5 ). • May be taken without regard to meals ( 2.1 ).",
    "warningsAndPrecautions_original": "Fenofibrate Tablets, USP are available containing 145 mg of fenofibrate, USP. \n                  The 145 mg tablets are white, film-coated, oval, unscored tablets debossed with M on one side of the tablet and FE4 on the other side. They are available as follows:\n                  \n                     \n                         NDC 68788-7932-3\tbottles of 30 tablets\n                     \n                         NDC 68788-7932-6\tbottles of 60 tablets\n                     \n                         NDC 68788-7932-9\tbottles of 90 tablets\n                     \n                         NDC 68788-7932-1\tbottles of 100 tablets\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.",
    "adverseReactions_original": "Fenofibrate tablets are contraindicated in:\n                  \n                     \n                        •patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)].\n                     \n                     \n                        •patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)].\n                     \n                     \n                        •patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)].\n                     \n                        •nursing mothers [see Use in Specific Populations (8.2)].\n                     \n                        •patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions (5.9)]."
}